Oncotelic Therapeutics, Inc. (OTLC)
OTCMKTS · Delayed Price · Currency is USD
0.0971
-0.0006 (-0.59%)
At close: Nov 28, 2025
Oncotelic Therapeutics Employees
Oncotelic Therapeutics had 26 employees as of December 31, 2024. The number of employees increased by 4 or 18.18% compared to the previous year.
Employees
26
Change (1Y)
4
Growth (1Y)
18.18%
Revenue / Employee
n/a
Profits / Employee
-$64,198
Market Cap
42.81M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 26 | 4 | 18.18% |
| Dec 31, 2023 | 22 | 0 | - |
| Dec 31, 2022 | 22 | 6 | 37.50% |
| Dec 31, 2021 | 16 | 0 | - |
| Dec 31, 2020 | 16 | 3 | 23.08% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| American Oncology Network | 1,914 |
| Glass House Brands | 374 |
| Silence Therapeutics | 116 |
| Elite Pharmaceuticals | 68 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
Oncotelic Therapeutics News
- 4 days ago - Oncotelic Therapeutics Inc. (OTCQB: OTLC) Anticipates Major Fair-Value Uptick Following New Independent JV Valuation - GlobeNewsWire
- 8 days ago - Oncotelic Therapeutics Inc. (OTCQB: OTLC) Emerging as Leader with New Independent JV Valuation - GlobeNewsWire
- 4 weeks ago - NetworkNewsAudio Announces Audio Press Release (APR) on Transforming Once-Marginal Drugs into Category-Changing Assets - GlobeNewsWire
- 4 weeks ago - Oncotelic Therapeutics Inc. (OTCQB: OTLC) at Forefront of Effort to Optimize Next-Generation Cancer Therapies - GlobeNewsWire
- 4 weeks ago - Sapu Nano to present at the 2025 San Antonio Breast Cancer Symposium (SABCS) Highlighting Sapu003 (Deciparticle™ Everolimus) - GlobeNewsWire
- 4 weeks ago - Oncotelic Therapeutics Inc. (OTCQB: OTLC) Working to Transform Underperforming Compounds into Next-Gen Cancer Therapies - GlobeNewsWire
- 5 weeks ago - Oncotelic to present at the 2025 San Antonio Breast Cancer Symposium (SABCS) Highlighting Sapu003 (Deciparticle™ Everolimus) - GlobeNewsWire
- 5 weeks ago - IBN Announces Latest Episode of The BioMedWire Podcast Featuring Return of Dr. Vuong Trieu, CEO of Oncotelic Therapeutics Inc. - GlobeNewsWire